{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:17:10Z","timestamp":1789172230373,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10549-026-08031-2","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:57:04Z","timestamp":1784537824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B)"],"prefix":"10.1007","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7285-9426","authenticated-orcid":false,"given":"Meiko","family":"Nishimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Funasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasagu","family":"Kurozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyo","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsunori","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsugu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayo","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"8031_CR1","doi-asserted-by":"crossref","unstructured":"Gradishar Wj MM, Abraham J et al NCCN Guidelines\u00ae breast cancer, version 5. 2025","DOI":"10.6004\/jnccn.2025.0053"},{"issue":"12","key":"8031_CR2","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML, Kim S-B, Tokunaga E, Aftimos P, Saura C, O\u2019Shaughnessy J, Harbeck N, Carey LA, Curigliano G, Llombart-Cussac A, Lim E, Garc\u00eda Tinoco MDLL, Sohn J, Mattar A, Zhang Q, Huang C-S, Hung C-C, Martinez Rodriguez JL, Ru\u00edz Borrego M, Nakamura R, Pradhan KR, Cramer von Laue C, Barrett E, Cao S, Wang XA, Smyth LM, Bidard F-C (2025) Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 392(12):1189\u20131202. https:\/\/doi.org\/10.1056\/NEJMoa2410858","journal-title":"N Engl J Med"},{"issue":"28","key":"8031_CR3","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier M-A, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, Garc\u00eda S\u00e1enz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cort\u00e9s J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A (2022) Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor\u2013positive, Human Epidermal Growth Factor receptor 2\u2013negative advanced breast cancer: results from the randomized phase III EMERALD trial. JCO 40(28):3246\u20133256. https:\/\/doi.org\/10.1200\/JCO.22.00338","journal-title":"JCO"},{"issue":"22","key":"8031_CR4","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS (2023) Capivasertib in hormone receptor\u2013positive advanced breast cancer. N Engl J Med 388(22):2058\u20132070. https:\/\/doi.org\/10.1056\/NEJMoa2214131","journal-title":"N Engl J Med"},{"key":"8031_CR5","doi-asserted-by":"publisher","unstructured":"Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen Y-M, Turner S, Kanakamedala H, Hsu W-C, Chia S (2024) Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol 25(12):e629\u2013e638. https:\/\/doi.org\/10.1016\/S1470-2045(24)00673-9","DOI":"10.1016\/S1470-2045(24)00673-9"},{"issue":"24","key":"8031_CR6","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.22.02392","volume":"41","author":"K Kalinsky","year":"2023","unstructured":"Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, Ahn H, Trivedi MS, Novik Y, Tiersten A, Raptis G, Baer LN, Oh SY, Zelnak AB, Wisinski KB, Andreopoulou E, Gradishar WJ, Stringer-Reasor E, Reid SA, O\u2019Dea A, O\u2019Regan R, Crew KD, Hershman DL (2023) Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 Inhibition in hormone receptor\u2013positive, Human Epidermal Growth Factor receptor 2\u2013negative metastatic breast cancer: MAINTAIN trial. JCO 41(24):4004\u20134013. https:\/\/doi.org\/10.1200\/JCO.22.02392","journal-title":"JCO"},{"issue":"17","key":"8031_CR7","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1200\/JCO.23.01940","volume":"42","author":"EL Mayer","year":"2024","unstructured":"Mayer EL, Ren Y, Wagle N et al (2024) PACE: a randomized phase II study of fulvestrant, palbociclib, and avelumab after progression on cyclin-dependent kinase 4\/6 inhibitor and aromatase inhibitor for hormone receptor-Positive\/Human Epidermal Growth Factor receptor-negative metastatic breast cancer. J Clin Oncol 42(17):2050\u20132060","journal-title":"J Clin Oncol"},{"issue":"18","key":"8031_CR8","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1200\/JCO-24-01865","volume":"43","author":"A Llombart-Cussac","year":"2025","unstructured":"Llombart-Cussac A, Harper-Wynne C, Perello A, Hennequin A, Fern\u00e1ndez-Ortega A, Colleoni M, Mar\u00edn S, Quiroga V, Medioni J, Iranzo V, Wheatley D, Del Barco Berr\u00f3n S, Ant\u00f3n A, Dobi E, Ruiz-Borrego M, Alcal\u00e1-L\u00f3pez D, P\u00e9rez-Escuredo J, Antonarelli G, Sampayo-Cordero M, P\u00e9rez-Garc\u00eda JM, Cort\u00e9s J (2025) Second-line endocrine therapy with or without palbociclib rechallenge in patients with hormone receptor\u2013Positive\/Human Epidermal Growth Factor receptor 2\u2013negative advanced breast cancer: PALMIRA trial. JCO 43(18):2084\u20132093. https:\/\/doi.org\/10.1200\/JCO-24-01865","journal-title":"JCO"},{"issue":"9","key":"8031_CR9","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO-24-02086","volume":"43","author":"K Kalinsky","year":"2025","unstructured":"Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Mu\u00f1oz M, Lai J-I, Knoderer H, Sandoval C, Chawla AR, Nguyen B, Zhou Y, Ravenberg E, Litchfield LM, Smyth L, Wander SA (2025) Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 Inhibition: results from the phase III postMONARCH trial. JCO 43(9):1101\u20131112. https:\/\/doi.org\/10.1200\/JCO-24-02086","journal-title":"JCO"},{"issue":"3","key":"8031_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl 48(3):452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transpl"},{"key":"8031_CR11","doi-asserted-by":"crossref","unstructured":"De Laurentiis M MFA, Gilgorov J et al (2025 December 9\u201312) Alpelisib plus fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer after a CDK4\/6 inhibitor (EPIK-B5): phase III, randomized, double-blind, placebo-controlled, multicenter study. In 2025 San Antonio Breast Conference Symposium, San Antonio, TX Abstract, RF7\u201302","DOI":"10.1158\/1557-3265.SABCS25-RF7-02"},{"issue":"1","key":"8031_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","volume":"23","author":"JO Brett","year":"2021","unstructured":"Brett JO, Spring LM, Bardia A, Wander SA (2021) ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res 23(1):85. https:\/\/doi.org\/10.1186\/s13058-021-01462-3","journal-title":"Breast Cancer Res"},{"issue":"25","key":"8031_CR13","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","volume":"34","author":"C Fribbens","year":"2016","unstructured":"Fribbens C, O\u2019Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S, Jiang J, Bartlett CH, Koehler M, Dowsett M, Bliss JM, Johnston SRD, Turner NC (2016) Plasma ESR1 mutations and the treatment of estrogen receptor\u2013positive advanced breast cancer. JCO 34(25):2961\u20132968. https:\/\/doi.org\/10.1200\/JCO.2016.67.3061","journal-title":"JCO"},{"issue":"4","key":"8031_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I et al (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17(4):425\u2013439","journal-title":"The Lancet Oncol"},{"issue":"8","key":"8031_CR15","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/1078-0432.CCR-21-3276","volume":"28","author":"SM Tolaney","year":"2022","unstructured":"Tolaney SM, Toi M, Neven P, Sohn J, Grischke E-M, Llombart-Cussac A, Soliman H, Wang H, Wijayawardana S, Jansen VM, Litchfield LM, Sledge GW (2022) Clinical significance of PIK3CA and ESR1 mutations in Circulating Tumor DNA: analysis from the MONARCH 2 study of abemaciclib plus fulvestrant. Clin Cancer Res 28(8):1500\u20131506. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3276","journal-title":"Clin Cancer Res"},{"issue":"34","key":"8031_CR16","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cort\u00e9s J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O\u2019Shaughnessy J, Rastogi P (2020) Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, Early breast cancer (monarchE). JCO 38(34):3987\u20133998. https:\/\/doi.org\/10.1200\/JCO.20.02514","journal-title":"JCO"},{"issue":"14","key":"8031_CR17","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.18.00925","volume":"37","author":"NC Turner","year":"2019","unstructured":"Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, DeMichele A, Harbeck N, Andr\u00e9 F, Bayar MA, Michiels S, Zhang Z, Giorgetti C, Arnedos M, Huang Bartlett C, Cristofanilli M (2019) Cyclin E1 expression and palbociclib efficacy in Previously treated hormone receptor\u2013positive metastatic breast cancer. JCO 37(14):1169\u20131178. https:\/\/doi.org\/10.1200\/JCO.18.00925","journal-title":"JCO"},{"key":"8031_CR18","doi-asserted-by":"publisher","unstructured":"Bardia A, Su F, Solovieff N, Im S-A, Sohn J, Lee KS, Campos-Gomez S, Jung KH, Colleoni M, V\u00e1zquez RV, Franke F, Hurvitz S, Harbeck N, Chow L, Taran T, Rodriguez Lorenc K, Babbar N, Tripathy D, Lu Y-S (2021) Genomic profiling of Premenopausal HR+ and HER2\u2013 metastatic breast cancer by Circulating Tumor DNA and association of genetic alterations with Therapeutic response to endocrine therapy and ribociclib. JCO Precis Oncol (5):1408\u20131420. https:\/\/doi.org\/10.1200\/PO.20.00445","DOI":"10.1200\/PO.20.00445"},{"issue":"1","key":"8031_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ (2015) The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(14)71159-3","journal-title":"The Lancet Oncol"},{"issue":"6","key":"8031_CR20","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.ccell.2017.11.006","volume":"32","author":"X Gong","year":"2017","unstructured":"Gong X, Litchfield LM, Webster Y, Chio L-C, Wong SS, Stewart TR, Dowless M, Dempsey J, Zeng Y, Torres R, Boehnke K, Mur C, Marug\u00e1n C, Baquero C, Yu C, Bray SM, Wulur IH, Bi C, Chu S, Qian H-R, Iversen PW, Merzoug FF, Ye XS, Reinhard C, De Dios A, Du J, Caldwell CW, Lallena MJ, Beckmann RP, Buchanan SG (2017) Genomic aberrations that activate D-type cyclins are associated with enhanced sensitivity to the CDK4 and CDK6 inhibitor abemaciclib. Cancer Cell 32(6):761\u2013776.e6. https:\/\/doi.org\/10.1016\/j.ccell.2017.11.006","journal-title":"Cancer Cell"},{"issue":"3","key":"8031_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/jnci\/djaa087","volume":"113","author":"B O\u2019Leary","year":"2021","unstructured":"O\u2019Leary B, Cutts RJ, Huang X, Hrebien S, Liu Y, Andr\u00e9 F, Loibl S, Loi S, Garcia-Murillas I, Cristofanilli M, Bartlett CH, Turner NC (2021) Circulating Tumor DNA markers for Early progression on fulvestrant with or without palbociclib in ER+ advanced breast cancer. JNCI: J Natl Cancer Inst 113(3):309\u2013317. https:\/\/doi.org\/10.1093\/jnci\/djaa087","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"1","key":"8031_CR22","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41467-019-09068-2","volume":"10","author":"L Formisano","year":"2019","unstructured":"Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee K-M, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O\u2019Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL (2019) Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer. Nat Commun 10(1):1373. https:\/\/doi.org\/10.1038\/s41467-019-09068-2","journal-title":"Nat Commun"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08031-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08031-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08031-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:54:18Z","timestamp":1785844458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08031-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8031"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08031-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9265904\/v1","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SK has received honoraria from Kyowa Kirin Co., Ltd., Daiichi-Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., MSD K.K., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Pfizer Japan Inc. CF has received honoraria from Daiichi-Sankyo Co., Ltd., Eisai Co., Ltd., Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., MSD K.K., and Eli Lilly Japan K.K., and material from Daiichi-Sankyo Co., Ltd. YF has received honoraria from Eisai Co., Ltd., Daiichi-Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Taiho Pharmaceutical Co., Ltd., MSD K.K., Chugai Pharmaceutical Co., Ltd., and Astellas Pharma Inc. AY has received honoraria from Pfizer Japan Inc., AstraZeneca K.K., and Chugai Pharmaceutical Co., Ltd. SW has received honoraria from Daiichi-Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., MSD K.K., Eli Lilly Japan K.K., Kyowa Kirin Co., Ltd., Eisai Co., Ltd., and Pfizer Japan Inc. TT has received honoraria from Daiichi-Sankyo Co., Ltd., Eli Lilly Japan K.K., Gilead Sciences, and MSD K.K. HS has received honoraria from Daiichi-Sankyo Co., Ltd., Eli Lilly Japan K.K., Gilead Sciences, AstraZeneca K.K., and Pfizer Japan Inc. HS has received research funding (outside of submitting work to her institution): Eli Lilly Japan K.K. YO has received honoraria from Eli Lilly Japan K.K., Pfizer Japan Inc., Daiichi-Sankyo Co., Ltd., and AstraZeneca K.K. TK has received grants from Eli Lilly Japan K.K., AstraZeneca K.K., Guardant Health, Daiichi-Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Be One, and Eisai Co., Ltd. TK has received consulting fees from Daiichi-Sankyo Co., Ltd., Astellas Pharma Inc., and received honoraria from Daiichi-Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Gilead Sciences, Astellas Pharma Inc., Eisai Co., Ltd., AstraZeneca K.K., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and MSD K.K. TK has received payment for expert testimony from Astellas Pharma Inc. TK has received support for attending meetings and\/or travel from Pfizer Japan Inc., and Eisai Co., Ltd. TK has participated on a Data Safety Monitoring Board or Advisory Board from Daiichi-Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Gilead Sciences, OncoTherapy Science, Eisai Co., Ltd., Astra Zeneca K.K., Taiho Pharmaceutical Co., Ltd., and Be One. TK received equipment, materials, drugs, medical writing, gifts, and other services from Daiichi-Sankyo Co., Ltd. The other authors have no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"18"}}